ArticleOpen heart2026
Equitable lipid optimisation through a data-driven, pharmacist-led secondary prevention pathway.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in the UK, with raised cholesterol contributing to 25%-28% of ASCVD deaths. Despite well-established guidelines, cholesterol levels remain suboptimally managed and can vary based on ethnicity, sex and socioeconomic deprivation, potentially leading to disproportionate cardiovascular risk for those living at these intersections. Pharmacist-led lipid clinics may reduce variation through structured review and continuity of care. This study evaluates whether automating the detection and referral of high-risk patients to a pharmacist-led clinic is associated with improved attainment of low-density lipoprotein cholesterol (LDL-C) among post-acute coronary syndrome patients in a West London borough, and whether outcomes vary by sex, ethnicity and socioeconomic deprivation.
methodsPatients with established ASCVD and residual elevated lipid levels were identified using the International Classification of Diseases, 10th revision and Systematised Nomenclature of Medicine coding and referred to a pharmacist-led review. Sex, ethnicity, age and index of multiple deprivation (IMD) were automatically extracted. The review involved a structured consultation, treatment intensification where required, and follow-up at agreed intervals. The primary outcome was attainment of LDL-C ≤2.0 mmol/L in line with National Institute for Health and Care Excellence recommendations assessed using a pre-post design.
resultsAmong 204 secondary prevention patients, 65% were from ethnically diverse backgrounds and 71% were male. Mean baseline LDL-C was 3.39 mmol/L and 13% were not actively receiving lipid-lowering therapy. Attendance by IMD quintile was 7.4% (most deprived), 34%, 33%, 13% and 12% (least deprived). Following the intervention, mean LDL-C reduced to 1.97 mmol/L with 70.6% achieving targets. Reductions were similar across sex, ethnicity and IMD quintile.
conclusionsA data-driven, pharmacist-led pathway was associated with significant LDL-C reduction. Among those who engaged, target attainment was similar across sex, ethnicity and IMD quintile, although low engagement from the most deprived quintile highlights that equitable reach has not yet been achieved. Further work is required to address upstream barriers and evaluate long-term sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.